Physician profile
Ryan D Freeland
NPI 1942265178
$10,017.40
in general payments reported to CMS, 2019-2025
31 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $181 · 2021: $6,757 · 2022: $489 · 2023: $640 · 2024: $717 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,401.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $6,446.92 | 2021-2022 | |
| Abbvie INC. | $602.37 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $371.01 | 2020-2025 | |
| Genzyme Corporation | $321.00 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $232.46 | 2020-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $220.34 | 2022-2025 | Sotyktu |
| Amgen INC. | $204.10 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $186.25 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $135.36 | 2020-2025 | |
| Janssen Biotech, INC. | $133.08 | 2020-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $123.80 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.98 | 2022-2025 | Spevigo, Cyltezo |
| Ucb, INC. | $118.95 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $102.84 | 2022-2025 | Adbry |
| Incyte Corporation | $101.29 | 2022-2025 | Opzelura |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $88.02 | 2023-2025 | Hadlima |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $74.74 | 2023-2025 | Siliq, Cabtreo |
| Galderma Laboratories, L.P. | $74.34 | 2022-2025 | Nemluvio, Aklief |
| Pfizer INC. | $63.46 | 2022-2025 | |
| Dusa Pharmaceuticals, INC. | $38.52 | 2019 | |
| Sandoz INC. | $33.83 | 2023-2024 | Hyrimoz |
| Dermavant Sciences, INC. | $31.71 | 2022-2023 | Vtama |
| Journey Medical Corporation | $28.80 | 2024-2025 | |
| Almirall LLC | $28.44 | 2021-2023 | Seysara |
| Fresenius Kabi USA, LLC | $25.30 | 2023 | Idacio |
| Vyne Pharmaceuticals INC. | $24.71 | 2020 | |
| Kerecis Limited | $24.54 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Sanofi-Aventis U.S. LLC | $18.79 | 2021 | |
| Verrica Pharmaceuticals INC. | $15.07 | 2024 | Ycanth |
| Lnhc, INC | $13.75 | 2025 | Zelsuvmi |
| Botanix Sb INC | $13.63 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Freeland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.